Literature DB >> 322390

Immunotherapy of cancer.

E C Holmes, D L Morton, F R Eilber.   

Abstract

Clinical studies have indicated a close relationship between immunological competency and the growth of human cancer. Studies in animal systems have indicated that immunological mechanisms are important in host-tumor existence. A number of agents are in the process of being evaluated for their immunotherapeutic potential in patients with cancer. These include levamisole, bacille Calmette Guérin (BCG) and Corynebacterium parvum. While the precise role of these agents in the treatment of human malignancy remains to be clearly defined, they do appear to be useful as adjuncts to other forms of cancer therapy such as radiation therapy, chemotherapy and surgical operation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 322390      PMCID: PMC1237466     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  30 in total

1.  [Stimulation of the reticuloendothelial system and development of experimental malignant tumors].

Authors:  B N HALPERN; G BIOZZI; C STIFFEL
Journal:  C R Seances Soc Biol Fil       Date:  1962

2.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

Authors:  G KLEIN; H O SJOGREN; E KLEIN; K E HELLSTROM
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

3.  Immunity to methylcholanthrene-induced sarcomas.

Authors:  R T PREHN; J M MAIN
Journal:  J Natl Cancer Inst       Date:  1957-06       Impact factor: 13.506

4.  The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes.

Authors:  H S LAWRENCE
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

5.  The role of the reticuloendothelial system in the host reaction to neoplasia.

Authors:  L J OLD; B BENACERRAF; D A CLARKE; E A CARSWELL; E STOCKERT
Journal:  Cancer Res       Date:  1961-10       Impact factor: 12.701

Review 6.  BCG and cancer (first of two parts).

Authors:  R C Bast; B Zbar; T Borsos; H J Rapp
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

Review 7.  Transfer-factor therapy of malignancy.

Authors:  J A Neidhart; A F LoBuglio
Journal:  Semin Oncol       Date:  1974-12       Impact factor: 4.929

8.  [Corynebacterium parvum in advanced cancers. 1st evaluation of the therapeutic activity of this immunostimulin].

Authors:  L Israël; B Halpern
Journal:  Nouv Presse Med       Date:  1972-01-01

9.  Active immunotherapy for acute lymphoblastic leukaemia.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F De Vassal
Journal:  Lancet       Date:  1969-04-05       Impact factor: 79.321

Review 10.  Corynebacterium parvum as an immunotherapeutic anticancer agent.

Authors:  M T Scott
Journal:  Semin Oncol       Date:  1974-12       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.